Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives

In this podcast episode, James A. Davis, PharmD, BCOP, and Kelley L. Julian, PharmD, BCOP, discuss evidence-based strategies for managing smoldering and newly diagnosed multiple myeloma, including:

• Risk stratification and treatment selection for smoldering multiple myeloma
• Anti-CD38–based regimens for transplant-eligible and transplant-ineligible patients
• Clinical evidence supporting triplet and quadruplet therapies
• MRD assessment and response-adapted treatment strategies
• Frailty, transplant eligibility, and individualized treatment selection
• Subcutaneous anti-CD38 administration and premedication requirements
• Pharmacist-led supportive care, toxicity management, dose modification, and patient counseling

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Presenters:
James A. Davis, PharmD, BCOP
Clinical Pharmacy Specialist, Myeloma/Lymphoma
The Medical University of South Carolina, Hollings Cancer Center
Affiliate Assistant Professor
MUSC College of Pharmacy
Charleston, South Carolina

Kelley L. Julian, PharmD, BCOP
Hematology/BMT Pharmacy Supervisor
PGY2 Oncology Pharmacy Residency Program Director
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah

Link to full program: 
https://bit.ly/4qaRb7n

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.